Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes

  1. Amanda R Dicks
  2. Grigory I Maksaev
  3. Zainab Harissa
  4. Alireza Savadipour
  5. Ruhang Tang
  6. Nancy Steward
  7. Wolfgang Liedtke
  8. Colin G Nichols
  9. Chia-Lung Wu
  10. Farshid Guilak  Is a corresponding author
  1. Washington University in St. Louis, United States
  2. Regeneron Pharmaceuticals, United States
  3. University of Rochester, United States

Abstract

Mutations in the TRPV4 ion channel can lead to a range of skeletal dysplasias. However, the mechanisms by which TRPV4 mutations lead to distinct disease severity remain unknown. Here, we use CRISPR-Cas9-edited human induced pluripotent stem cells (hiPSCs) harboring either the mild V620I or lethal T89I mutations to elucidate the differential effects on channel function and chondrogenic differentiation. We found that hiPSC-derived chondrocytes with the V620I mutation exhibited increased basal currents through TRPV4. However, both mutations showed more rapid calcium signaling with a reduced overall magnitude in response to TRPV4 agonist GSK1016790A compared to wildtype. There were no differences in overall cartilaginous matrix production, but the V620I mutation resulted in reduced mechanical properties of cartilage matrix later in chondrogenesis. mRNA sequencing revealed that both mutations upregulated several anterior HOX genes and downregulated antioxidant genes CAT and GSTA1 throughout chondrogenesis. BMP4 treatment upregulated several essential hypertrophic genes in WT chondrocytes; however, this hypertrophic maturation response was inhibited in mutant chondrocytes. These results indicate that the TRPV4 mutations alter BMP signaling in chondrocytes and prevent proper chondrocyte hypertrophy, as a potential mechanism for dysfunctional skeletal development. Our findings provide potential therapeutic targets for developing treatments for TRPV4-mediated skeletal dysplasias.

Data availability

All RNAseq data files generated and reported in this study are available on GEO (accession number GSE225446, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225446).

The following data sets were generated

Article and author information

Author details

  1. Amanda R Dicks

    Department of Biomedical Engineering, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  2. Grigory I Maksaev

    Department of Cell Biology and Physiology, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  3. Zainab Harissa

    Department of Biomedical Engineering, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  4. Alireza Savadipour

    Department of Orthopedic Surgery, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  5. Ruhang Tang

    Department of Orthopedic Surgery, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  6. Nancy Steward

    Department of Orthopedic Surgery, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  7. Wolfgang Liedtke

    Regeneron Pharmaceuticals, Tarrytown, United States
    Competing interests
    Wolfgang Liedtke, Patents on TRPV4 inhibitors have been licensed to TRPblue. Dr. Liedtke is an employee of Regeneron Pharmaceuticals.(US Patents 9,701,675; 10,329,265; and 11,014,896)..
  8. Colin G Nichols

    Department of Cell Biology and Physiology, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4929-2134
  9. Chia-Lung Wu

    Department of Orthopaedics and Rehabilitation, University of Rochester, Rochester, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9598-7036
  10. Farshid Guilak

    Department of Orthopedic Surgery, Washington University in St. Louis, St Louis, United States
    For correspondence
    guilak@wustl.edu
    Competing interests
    Farshid Guilak, Patents on TRPV4 inhibitors licensed to TRPblue Inc. (US Patents 9,701,675; 10,329,265; and 11,014,896)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7380-0330

Funding

National Institutes of Health (AG15768)

  • Farshid Guilak

National Institutes of Health (AG46927)

  • Farshid Guilak

National Institutes of Health (ar072999)

  • Farshid Guilak

National Institutes of Health (AR075899)

  • Chia-Lung Wu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Dicks et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,181
    views
  • 163
    downloads
  • 11
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Amanda R Dicks
  2. Grigory I Maksaev
  3. Zainab Harissa
  4. Alireza Savadipour
  5. Ruhang Tang
  6. Nancy Steward
  7. Wolfgang Liedtke
  8. Colin G Nichols
  9. Chia-Lung Wu
  10. Farshid Guilak
(2023)
Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes
eLife 12:e71154.
https://doi.org/10.7554/eLife.71154

Share this article

https://doi.org/10.7554/eLife.71154

Further reading

    1. Stem Cells and Regenerative Medicine
    Simon Perrin, Maria Ethel ... Céline Colnot
    Tools and Resources

    Bone regeneration is mediated by skeletal stem/progenitor cells (SSPCs) that are mainly recruited from the periosteum after bone injury. The composition of the periosteum and the steps of SSPC activation and differentiation remain poorly understood. Here, we generated a single-nucleus atlas of the periosteum at steady state and of the fracture site during the early stages of bone repair (https://fracture-repair-atlas.cells.ucsc.edu). We identified periosteal SSPCs expressing stemness markers (Pi16 and Ly6a/SCA1) and responding to fracture by adopting an injury-induced fibrogenic cell (IIFC) fate, prior to undergoing osteogenesis or chondrogenesis. We identified distinct gene cores associated with IIFCs and their engagement into osteogenesis and chondrogenesis involving Notch, Wnt, and the circadian clock signaling, respectively. Finally, we show that IIFCs are the main source of paracrine signals in the fracture environment, suggesting a crucial paracrine role of this transient IIFC population during fracture healing. Overall, our study provides a complete temporal topography of the early stages of fracture healing and the dynamic response of periosteal SSPCs to injury, redefining our knowledge of bone regeneration.

    1. Stem Cells and Regenerative Medicine
    Suying Liu, Sarah E Adams ... Peter Kurre
    Research Article

    Hematopoietic dysfunction has been associated with a reduction in the number of active precursors. However, precursor quantification at homeostasis and under diseased conditions is constrained by the scarcity of available methods. To address this issue, we optimized a method for quantifying a wide range of hematopoietic precursors. Assuming the random induction of a stable label in precursors following a binomial distribution, estimates depend on the inverse correlation between precursor numbers and the variance of precursor labeling among independent samples. Experimentally validated to cover the full dynamic range of hematopoietic precursors in mice (1–105), we utilized this approach to demonstrate that thousands of precursors, which emerge after modest expansion during fetal-to-adult transition, contribute to native and perturbed hematopoiesis. We further estimated the number of precursors in a mouse model of Fanconi Anemia, showcasing how repopulation deficits can be classified as autologous (cell proliferation) and non-autologous (lack of precursor). Our results support an accessible and reliable approach for precursor quantification, emphasizing the contemporary perspective that native hematopoiesis is highly polyclonal.